Learn more about our allogeneic CAR T clinical trials:


PBCAR0191 is an investigational anti-CD19 allogeneic CAR T candidate being evaluated in a Phase 1/2a clinical trial of adult subjects with relapsed or refractory (R/R) non-Hodgkin lymphoma, including patients with mantle cell lymphoma, an aggressive subtype of NHL, or R/R B-cell precursor acute lymphoblastic leukemia. This study is a multicenter, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study. Made from donor-derived T cells modified using our ARCUS genome editing technology, PBCAR0191 recognizes the well characterized tumor cell surface protein CD19, an important and validated target in several B-cell cancers and is designed to avoid graft-versus-host disease, a significant complication associated with donor-derived, cell-based therapies. All subjects who receive a dose of PBCAR0191 will be followed in a separate long-term follow-up study for 15 years after exiting this study. We have received orphan drug designation for PBCAR0191 from the U.S. Food and Drug Administration for the treatment of ALL and MCL, as well as Fast Track Designation for PBCAR0191 for the treatment of B-ALL.

For more information, visit www.clinicaltrials.gov, study identifier number NCT03666000.

PBCAR19B is a next-generation, anti-CD19 immune-evading stealth cell candidate being evaluated in a Phase 1 study of adult subjects with relapsed/refractory non-Hodgkin lymphoma. This study is a nonrandomized, open-label, single-dose, dose-escalation and dose-expansion study.  PBCAR19B is designed to improve the expansion and persistence of allogeneic CAR T cells following infusion by reducing rejection by T cells and natural killer (NK) cells. In addition to the CAR gene, the PBCAR19B stealth cell vector carries a short hairpin RNA that suppresses expression of beta-2 microglobulin, a component of Class I Major Histocompatibility Complex (MHC) molecules found on the cell surface. Reducing or knocking-down Class I MHC expression on allogeneic CAR T cells has been shown to reduce CAR T cell killing by cytotoxic T cells. The PBCAR19B vector also carries an HLA-E gene intended to reduce rejection of CAR T cells by NK cells that can be stimulated as a result of reduced MHC molecule expression on the cell surface.

For more information, visit www.clinicaltrials.gov, study identifier number NCT04649112.

PBCAR20A is an investigational anti-CD20 allogeneic CAR T candidate being evaluated in a Phase 1/2a study of adult subjects with a relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including those with R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study. Made from donor-derived T cells modified using our ARCUS genome editing technology, PBCAR20A targets the validated tumor cell surface target CD20, and like our other allogeneic CAR T candidates, is designed to avoid graft-versus-host disease, a significant complication associated with donor-derived, cell-based therapies. All subjects who receive a dose of PBCAR20A will be followed in a separate long-term follow-up (LTFU) study for 15 years after exiting this study. We have received orphan drug designation for PBCAR20A from the U.S. Food and Drug Administration for the treatment of MCL.

For more information, visit www.clinicaltrials.gov, study identifier number NCT04030195.

PBCAR269A is an investigational allogeneic BCMA-targeted CAR T cell therapy candidate being evaluated in a Phase 1/2a study of adult subjects with relapsed or refractory (R/R) multiple myeloma. This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study. In a separate arm of this study, subjects will receive PBCAR269A in combination with nirogacestat, a gamma secretase inhibitor (GSI) being developed by SpringWorks Therapeutics. Emerging preclinical and clinical data suggest that a GSI may increase antitumor efficacy of BCMA-targeted autologous CAR T therapy in patients with R/R multiple myeloma. All patients who receive a dose of PBCAR269A will be followed in a separate long-term follow-up study for 15 years after exiting this study. The U.S. Food and Drug Administration granted Fast Track Designation to PBCAR269A for the treatment of R/R multiple myeloma for which the FDA previously granted Orphan Drug Designation.

For more information, visit www.clinicaltrials.gov, study identifier number NCT04171843.

Expanded Access


Precision BioSciences is currently investigating multiple off-the-shelf allogeneic CAR T cell therapy candidates as potential treatment options for patients with hematologic blood cancers. Precision does not currently offer patients Expanded Access to investigational therapies outside of clinical trials. We believe that facilitating patient participation in our ongoing clinical trials is the best way to speed investigation and subsequent approval of candidate therapies for broad access by providing a rigorous assessment of the products’ benefits, risks, and appropriate uses for patients. Eligibility requirements and more information about our clinical trials is available at clinicaltrials.gov.